Presepsin and Pentraxin-3 as Diagnostic and Severity Biomarkers in Community-Acquired Pneumonia: A Pilot Study
Open Access
Abstract
Background: Biomarkers reflecting innate immune activation may complement clinical severity scores in community-acquired pneumonia (CAP). This study evaluated serum presepsin and pentraxin-3 (PTX3) concentrations in patients with CAP and healthy controls and examined their associations with pneumonia severity. Methods: Ninety participants were analyzed, including 45 patients with CAP and 45 healthy controls. Pneumonia severity was assessed using the Pneumonia Severity Index (PSI) and CURB-65. Group comparisons, Spearman correlation analyses, receiver operating characteristic (ROC) analyses, and an exploratory multivariable logistic regression model were performed. Results: Presepsin concentrations were higher in patients with CAP than in healthy controls (2157 [1824–2524] vs. 1749 [1652–1879] pg/mL; p < 0.001), as were PTX3 concentrations (2.15 [1.76–2.87] vs. 1.67 [1.40–2.11] ng/mL; p < 0.001). For discrimination of CAP from healthy controls, the AUC was 0.822 (95% CI 0.728–0.902) for presepsin and 0.706 (95% CI 0.598–0.810) for PTX3. Among patients with CAP, presepsin correlated with PSI (rho = 0.552, p < 0.001) and CURB-65 (rho = 0.600, p < 0.001), while PTX3 showed stronger correlations with PSI (rho = 0.691, p < 0.001) and CURB-65 (rho = 0.668, p < 0.001). For identifying PSI classes IV–V, the AUC was 0.647 for presepsin and 0.742 for PTX3. Conclusions: Both presepsin and PTX3 were elevated in CAP and were associated with increasing disease severity. Within this pilot sample, presepsin showed a numerically higher AUC for discrimination between CAP and healthy controls, whereas PTX3 showed stronger associations with severity. Larger prospective studies are required to validate these findings.Keywords
This publication has 20 references indexed in Scilit:
- Pentraxin-3 as a diagnostic and prognostic biomarker in inflammatory lung diseasesClinica Chimica Acta, 2026
- Dynamically monitoring pneumonia severity scores to predict the prognosis in patients with community-acquired pneumonia: an international, multicenter cohort studyRespiratory Medicine, 2025
- Community-Acquired PneumoniaJAMA, 2024
- Biomarkers: Are They Useful in Severe Community-Acquired Pneumonia?Seminars in Respiratory and Critical Care Medicine, 2024
- Presepsin in the diagnosis of sepsisClinica Chimica Acta, 2023
- The cutoff value of presepsin for diagnosing sepsis increases with kidney dysfunction, a cross-sectional observational studyMedicine, 2023
- Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of AmericaAmerican Journal of Respiratory and Critical Care Medicine, 2019
- A Prospective Study of Presepsin as an Indicator of the Severity of Community-Acquired Pneumonia in Emergency Departments: Comparison with Pneumonia Severity Index and CURB-65 ScoresLaboratory Medicine, 2019
- Admission Pentraxin‐3 Level Predicts Severity of Community‐Acquired Pneumonia Independently of EtiologyProteomics – Clinical Applications, 2018
- Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation studyThorax, 2003